Value-Added Medicines (VAM)
PLG partners with you across the entire VAM value chain - from clinical design to differentiated market access - across global markets.
Why Value-Added Medicines, why now
Value no longer comes only from a new molecule
Value-Added Medicines build on a known, well-characterised active substance and unlock new value through smarter formulation, delivery and positioning – improving compliance, outcomes and patient experience for diseases with well-understood safety profiles.
Five routes to value
- Repurposing — new indications for off-patent molecules (Article 84 pathway)
- Reformulation — long-acting oral solutions, extended-release suspensions, liposomal formulations
- Fixed-dose combinations — simplified regimens that drive adherence
- New routes of administration — e.g. subcutaneous vs intravenous switches that free up hospital and nursing capacity
- Device & digital optimisation — self-injection, connected delivery, fewer medication errors
For companies and investors: lifecycle extension, portfolio differentiation and localised price premiums — a capital-efficient route to growth.
The recognition gap
Good evidence often goes unrewarded.
VAM value is real, but HTA systems are built primarily to reward clinical superiority. Convenience, organisational benefit and improved safety create genuine system value – yet without the right strategy, value-added medicines can run into structural barriers that push price toward the lowest reference level:
- Reference-price cannibalisation — unsequenced geographic launches erode price across markets
- Disproportionate trial demands — payers ask for head-to-head comparative data the innovation wasn’t designed to generate
- Fragmented European pathways — AIFA, HAS, G-BA, NICE and others each reward different evidence; a single dossier rarely wins everywhere
VAM needs a partner who can convert soft benefits into hard, payer-recognised endpoints, across the whole lifecycle.
Local expertise where it counts
One value story, market by market
We translate incremental value into the specific endpoints each market’s payer archetype rewards: added clinical benefit in Germany, cash-releasing cost-offsets in the UK, care-pathway value in France, therapeutic positioning in Spain, holistic clinical-organisational-behavioural value in Italy — one consistent value story, adapted across the EU5.
Why partner with PLG
- Cross-functional synergy — clinical, regulatory, compliance, HTA and digital expertise under one roof, building one cohesive, payer-resilient narrative
- Early HTA engagement — parallel scientific dialogue before submission, aligning clinical design and avoiding disproportionate comparative-trial demands
- Proven track record — from transforming daily-injectable therapies to shifting the ownership of compliance
- Executive partnership — high-level, strategic guidance tailored for C-suite decision-making
For acquirers and investors: de-risk access, extend lifecycle and maximise asset value — turning incremental innovation into portfolio returns.